Clinical study of autologous cytokine induced killer cells combined with IL-2 for therapy of elderly patients with B-cell malignant lymphoma.
- Author:
Bo YANG
1
;
Xue-Chun LU
;
Hong-Li ZHU
;
Wei-Dong HAN
;
Yao WANG
;
Hui FAN
;
Su-Xia LI
;
Yang LIU
;
Han-Ren DAI
;
Shan-Qian YAO
Author Information
1. Department of Geriatric Hematology, Institute of Basic Medical Sciences, Chinese PLA General Hospital, Beijing 100853, China.
- Publication Type:Clinical Trial
- MeSH:
Aged;
Aged, 80 and over;
Cytokine-Induced Killer Cells;
immunology;
Female;
Humans;
Immunotherapy, Adoptive;
Interleukin-2;
therapeutic use;
Killer Cells, Natural;
immunology;
Lymphoma, B-Cell;
therapy;
Male;
Middle Aged;
Treatment Outcome
- From:
Journal of Experimental Hematology
2010;18(5):1244-1249
- CountryChina
- Language:Chinese
-
Abstract:
Objective of this study was to evaluate the effectiveness and safety of autologous cytokine induced killer (CIK) cells combined with IL-2 in treatment of elderly patients with B-cell malignant lymphoma. Peripheral blood mononuclear cells (PBMNC) were isolated from 9 elderly patients with B-cell malignant lymphoma, and then induced into CIK cells by IFN-γ, IL-2 and monoclonal antibody (mAb) against CD3. The autologous CIK cells [(2-3)×10(9)] thus obtained were infused back to individual patients, then followed by subcutaneous injection of IL-2 at single daily dose of 1×10(4) U/day for 10 consecutive days. The regimen was repeated every 4 weeks and total 64 cycles of CIK cell transfusion were completed. The changes in cellular immune function, tumor-related biological parameters, imaging characteristics, the condition of remission, quality of life and survival time were assessed. 7 patients received 8 cycles of CIK cell infusion, and 4 cycles were completed in 2 patients. The results showed that no adverse reaction was observed in all above mentioned patients. The percentages of CD3+, CD3+CD8+ and CD3+CD56+ increased significantly (p<0.05), and serum levels of β2-microglobulin and LDH were markedly decreased (p<0.05) after autologous CIK cell transfusion. The lymphoma symptoms were relieved with quality of life obviously elevated (p<0.01) in all patients. Complete remission was seen in 8 patients. Though one patient received 8 cycles of CIK cell transfusion therapy and achieved transient very good partial remission, but he died of acute large-area myocardial infarction and persistent progression of lymphoma. In conclusion, regimen of autologous CIK cells combined with IL-2 is safe and effective for the therapy of elderly patients with B-cell malignant lymphoma.
